肝炎診斷市場：策略性洞察與預測（2026-2035）

預計到 2026 年，肝炎診斷市場規模將達到 28.5 億美元，到 2035 年將達到 43.2 億美元，複合年成長率為 4.7%。

肝炎診斷市場正經歷重大變革，其驅動力在於向國家層級根除策略的模式轉移以及分子診斷技術融入常規臨床實踐。這一市場演變的特點是，人們日益認知到，延遲診斷會導致可預防的肝病進展和病毒持續感染，因此早期檢測已成為公共衛生工作的首要任務。先進的血清學檢測、核酸擴增技術和檢查室自動化技術的融合，使得在各種醫療機構中進行肝炎檢測變得更加快速、靈敏且更加普及。各國政府正在擴大國家肝炎根除計劃，將定期篩檢列為公共衛生優先事項，並增加對監測、血液篩檢、孕產婦保健計劃和社區檢測的投入。臨床管理越來越依賴準確的病毒檢測，而不僅僅是抗體篩檢。由於準確量化病毒複製對於啟動治療和監測治療效果至關重要，醫療專業人員正在採用基於PCR的病毒量檢測。隨著市場對自動化分子診斷平台、多參數檢測能力和數位連接的大量投資，肝炎診斷正在成為公共衛生基礎設施和疾病監測的關鍵組成部分。

市場促進因素

• 各國擴大肝炎根除計畫是推動肝炎診斷市場發展的主要動力。這些策略將定期篩檢作為公共衛生工作的重中之重。由於未確診的感染仍會導致慢性肝病，各國政府正在加大對監測、血液篩檢、孕產婦保健計畫和社區檢測的投入。診斷試劑生產商正在擴大其檢測套組產品範圍，以支援這些計劃，無論這些計劃採用集中式還是分散式檢測模式。檢測基礎設施的擴展增強了對肝炎診斷的長期需求，改善了診斷和治療之間的協調，並推動了肝炎診斷使用量的持續成長。分子診斷技術的日益普及透過實現精準的病毒檢測，進一步加速了市場成長。臨床管理越來越依賴精準的病毒檢測，而不僅僅是抗體篩檢。醫療專業人員正在採用基於PCR的病毒量檢測，因為準確量化病毒複製對於啟動治療和監測治療效果至關重要。診斷試劑生產商正在採用速度更快、多分子診斷平台，這些平台可以在不影響分析效能的前提下提高檢查室效率。分子診斷在肝炎檢測流程中的地位日益穩固。慢性肝病負擔的加重推動了對早期檢測和監測的需求。慢性肝炎仍是肝硬化和肝細胞癌的主要病因。由於延遲診斷會增加長期醫療成本和疾病負擔，早期檢測策略正在醫療保健系統中推廣。醫院正在將肝炎檢測納入更廣泛的肝病管理流程，而診斷檢查室也不斷提升其檢測能力。這種結構性整合正在維持篩檢、確診和監測等各個應用領域的需求。更嚴格的血液安全法規推動了對高靈敏度篩檢檢測的需求。血液安全取決於輸血傳染感染疾病的準確檢測。隨著核酸檢測縮短了診斷的“窗口期”，監管機構不斷加強對捐血篩檢的要求。血庫正在更新其檢測技術以符合不斷變化的監管標準，而製造商也在不斷開發更高通量的篩檢平台。

市場限制因素

• 高昂的實施成本持續限制資源匱乏的醫療體系中分子診斷技術的普及，這些系統的檢測基礎設施仍然不足。先進技術所需的巨額資金投入在資源受限的環境中構成了一大障礙。在一些開發中地區，由於訓練有素的檢查室人員和品質保證系統不足，診斷服務的可近性仍參差不齊。缺乏熟練人員和基礎設施限制了分子診斷技術的擴充性。先進的分子檢測技術並未被納入各醫療體系的保險覆蓋範圍，保險報銷政策的差異也持續影響技術的普及率。不一致的保險覆蓋政策為診斷服務提供者帶來了不確定性，並限制了患者的就醫途徑。此外，各司法管轄區之間複雜的法規差異也給尋求將新型診斷解決方案商業化的製造商帶來了合規負擔。

目錄

第1章執行摘要

• 市場概述
• 主要發現
• 分析師意見
• 策略建議

第2章：調查方法

• 調查設計
• 資料收集和調查方法
• 市場規模估算
• 預測模型
• 先決條件和限制

第3章 肝炎診斷市場：概述、市場規模與預測

• 市場定義和範圍
• 肝炎概述
• 病毒性肝炎的分類（甲型肝炎病毒、B型肝炎病毒、C型肝炎病毒、丁型肝炎病毒、戊型肝炎病毒）
• 疾病負擔與未滿足的診斷需求
• 流行病學和盛行率分析
  • 全球疾病盛行率
  • 確診患者人數
• 診斷流程和測試演算法
• 產業變化
• 主要市場趨勢
• 市場規模表現分析
• 市場預測

第4章 市場動態

• 市場促進因素
• 市場限制因素
• 市場機遇
• 市場挑戰

第5章 行業情勢

• 產業價值鏈分析
• 定價分析
• 還款狀態

第6章：創新趨勢

• 新型診斷技術
• 產品創新
• 臨床試驗分析
• 管道分析
• 技術藍圖
• 人工智慧在肝炎診斷的應用
• 與數位健康整合

第7章 監理情勢

• 法律規範
• 核准流程
• 合規要求

第8章：肝炎診斷市場：展望分析

• 分析：按技術平台
• 分析：依肝炎類型分類
• 分析：透過生物標記
• 分析：依樣本類型
• 分析：透過調查方法
• 分析：透過臨床應用

第9章：肝炎診斷市場：細分市場分析

• 按肝炎類型
  • 甲型肝炎（HAV）
  • 乙型肝炎（HBV）
  • 丙型肝炎（HCV）
  • 丁型肝炎（HDV）
  • 戊型肝炎（HEV）
• 按測試類型
  • 血清學檢測
  • 分子診斷
  • 肝功能檢查
  • 診斷影像和切片檢查
• 透過技術
  • 酵素免疫分析法（ELISA）
  • 聚合酵素鏈鎖反應（PCR）
  • 次世代定序（NGS）
  • 其他
• 依樣本類型
  • 全血
  • 血清和血漿
  • 乾血斑（DBS）
  • 其他
• 最終用戶
  • 醫院
  • 診斷檢查室
  • 學術研究機構
  • 其他

第10章：肝炎診斷市場：區域分析

• 北美洲
• 歐洲
• 亞太地區
• 南美洲
• 中東和非洲

第11章：肝炎診斷市場：國別分析

• 美國
• 加拿大
• 德國
• 英國
• 法國
• 義大利
• 西班牙
• 中國
• 日本
• 印度
• 韓國
• 澳洲
• 巴西
• 墨西哥
• 沙烏地阿拉伯
• 南非

第12章 競爭格局

• 市佔率分析
• 策略趨勢
• 併購、合作與聯盟
• 新產品發布

第13章：公司簡介

• F. Hoffmann-La Roche Ltd
• Abbott Laboratories
• Siemens Healthineers
• Danaher Corporation
• bioMerieux
• Bio-Rad Laboratories
• QuidelOrtho Corporation
• Hologic, Inc.
• QIAGEN
• Grifols SA

第14章：肝炎診斷市場：商業預測分析

第15章 投資與資金籌措分析

• 創業投資趨勢
• 政府資金
• 研發投資

第16章：未來展望

• 主要成長機遇
• 未來產業趨勢

The Hepatitis Diagnostics Market is expected to grow at a CAGR of 4.7% from a market value of USD 2.85 billion in 2026 to USD 4.32 billion in 2035.

The hepatitis diagnostics market is undergoing significant transformation driven by the paradigm shift toward national elimination strategies and the integration of molecular diagnostics into routine clinical practice. The market's evolution is characterized by the growing recognition that delayed diagnosis contributes to preventable liver disease progression and ongoing viral transmission, making early detection a public health priority. The convergence of advanced serological assays, nucleic acid amplification technologies, and laboratory automation is enabling faster, more sensitive, and increasingly accessible hepatitis testing across diverse healthcare settings. Governments are expanding national hepatitis elimination programs, establishing routine screening as a public health priority and increasing investments in surveillance, blood screening, maternal health programs, and community testing. Clinical management increasingly depends on precise viral detection rather than antibody screening alone, with healthcare providers incorporating PCR-based viral load testing because treatment initiation and response monitoring require accurate quantification of viral replication. The market is witnessing significant investment in automated molecular platforms, multiplex testing capabilities, and digital connectivity, positioning hepatitis diagnostics as a critical component of public health infrastructure and disease surveillance.

Market Drivers

• The expansion of national hepatitis elimination programs represents the primary driver for the hepatitis diagnostics market. National hepatitis elimination strategies establish routine screening as a public health priority. Governments are increasing investments in surveillance, blood screening, maternal health programs, and community testing because undiagnosed infections continue contributing to chronic liver disease. Diagnostic manufacturers are expanding assay availability to support these programs across centralized and decentralized laboratory settings. This broader testing infrastructure strengthens long-term demand for hepatitis diagnostics while improving linkage between diagnosis and treatment, resulting in sustained growth in hepatitis diagnostic utilization. The growing adoption of molecular diagnostics is further accelerating market growth by enabling precise viral detection. Clinical management increasingly depends on precise viral detection rather than antibody screening alone. Healthcare providers are incorporating PCR-based viral load testing because treatment initiation and response monitoring require accurate quantification of viral replication. Diagnostic companies are introducing faster multiplex molecular platforms capable of improving laboratory productivity without compromising analytical performance. Molecular diagnostics continue to strengthen their position within hepatitis testing algorithms. The increasing burden of chronic liver disease is driving demand for early detection and monitoring. Chronic hepatitis remains a major contributor to liver cirrhosis and hepatocellular carcinoma. Healthcare systems are expanding early detection strategies because delayed diagnosis increases long-term healthcare expenditure and disease burden. Hospitals are integrating hepatitis testing into broader liver disease management pathways while diagnostic laboratories continue upgrading testing capacity. This structural integration sustains demand across screening, confirmation, and monitoring applications. Strengthening blood safety regulations is increasing demand for sensitive screening assays. Blood safety depends on accurate detection of transfusion-transmissible infections. Regulatory authorities continue strengthening donor screening requirements because nucleic acid testing reduces diagnostic window periods. Blood banks are upgrading laboratory technologies to comply with evolving regulatory standards while manufacturers continue developing higher-throughput screening platforms.

Market Restraints

• High implementation costs continue limiting molecular diagnostic adoption in lower-resource healthcare systems where laboratory infrastructure remains inadequate. The significant financial investment required for advanced technologies creates barriers for resource-constrained settings. Diagnostic access remains uneven because trained laboratory personnel and quality assurance systems are insufficient in several developing regions. The shortage of skilled workforce and infrastructure limits the scalability of molecular diagnostics. Reimbursement variability continues affecting adoption rates because advanced molecular testing is not consistently covered across healthcare systems. Inconsistent coverage policies create uncertainty for diagnostic providers and limit patient access. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new diagnostic solutions.

Technology and Segment Insights

• The technology landscape is characterized by the growing importance of integrated diagnostic workflows and automation. Molecular diagnostics constitute the fastest-evolving testing segment because nucleic acid amplification techniques provide highly sensitive viral detection and accurate viral load quantification. Clinical treatment algorithms increasingly rely on PCR-based testing since antiviral initiation, treatment monitoring, and confirmation of sustained virologic response require precise measurement of viral replication. Laboratories are replacing conventional manual workflows with fully automated molecular platforms to improve turnaround time and analytical consistency. Serology tests remain essential for initial screening and disease staging. ELISA continues to be widely used for antibody and antigen detection. The segment analysis reveals that Hepatitis B represents the largest demand center because chronic infection requires lifelong monitoring rather than one-time diagnosis. Clinical management depends on a combination of serological markers and molecular viral load testing to determine disease activity, treatment eligibility, and therapeutic response. Healthcare providers are increasing routine HBV screening among pregnant women, blood donors, immunocompromised patients, and high-risk adults because undiagnosed infection continues contributing to preventable liver cirrhosis and hepatocellular carcinoma. Hepatitis C represents a significant segment due to the large undiagnosed population and the availability of curative therapies. Hepatitis A, D, and E represent smaller but important segments. Diagnostic laboratories account for the largest share of advanced hepatitis testing because centralized facilities perform confirmatory serology, nucleic acid testing, and treatment monitoring at scale. Healthcare systems are consolidating specialized testing into reference laboratories because automation improves operational efficiency while maintaining standardized quality assurance. Hospitals and academic research institutes are expanding testing capabilities. The integration of digital connectivity is becoming increasingly important because laboratories require real-time quality monitoring and operational efficiency to handle growing testing volumes.

Competitive and Strategic Outlook

• The competitive landscape features established diagnostics and life science companies alongside specialized infectious disease providers. Roche maintains a leading position in molecular hepatitis diagnostics through its cobas platform, offering highly sensitive HBV and HCV viral load assays, with a strategy focused on integrated molecular workflows and laboratory automation for high-throughput testing. Abbott offers comprehensive hepatitis testing across its Alinity and ARCHITECT platforms, combining serology and molecular diagnostics, emphasizing workflow efficiency, automation, and global accessibility for large laboratory networks. Siemens Healthineers provides automated immunoassay solutions through the Atellica portfolio, supporting high-volume hepatitis screening, with a strategy centered on digital laboratory integration and standardized diagnostic workflows. Danaher, through Cepheid, Beckman Coulter, and Leica Biosystems, delivers molecular and laboratory diagnostic solutions for infectious diseases, strengthening decentralized molecular testing alongside automated laboratory systems. QIAGEN specializes in molecular sample preparation and PCR technologies, supporting hepatitis detection with integrated molecular workflows, with strategic focus including syndromic testing, automation, and companion diagnostic partnerships. Bio-Rad develops quality-controlled immunoassays and molecular testing products for hepatitis diagnosis and blood screening, differentiating through quality assurance solutions and reference laboratory expertise. Companies are pursuing product portfolio expansion through innovation in molecular assays, automated platforms, and multiplex testing capabilities. Strategic collaborations between diagnostic manufacturers, pharmaceutical companies, and public health agencies are increasing, driven by the need for integrated care models combining screening, confirmatory testing, and therapeutic monitoring. Recent key developments include Roche launching the cobas MPX-E assay, a new 4-in-1 donor screening test for HIV, HCV, HBV, and HEV. GlaxoSmithKline announced positive results from B-Well 1 and B-Well 2 Phase III trials for bepirovirsen, demonstrating a functional cure rate for chronic hepatitis B infection. Reszon Diagnostics launched the RESZON HBsAg Rapid Test for qualitative detection of Hepatitis B surface antigen. Altona Diagnostics launched the AltoStar HDV RT-PCR Kit 1.5 for detection and quantification of Hepatitis D virus RNA. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

• The hepatitis diagnostics market is positioned for sustained growth driven by the convergence of national elimination programs, molecular diagnostic adoption, and expanding healthcare investment. The transition from episodic disease detection toward continuous disease management represents a fundamental shift in hepatitis care. While challenges related to high costs, infrastructure limitations, and reimbursement variability persist, strategic investments in technology, automation, and partnerships are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with hepatitis diagnostics evolving into a critical component of public health infrastructure, supporting early diagnosis, treatment monitoring, and disease surveillance across global healthcare systems.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Hepatitis Diagnostics Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Hepatitis Disease Overview
• 3.3 Classification of Viral Hepatitis (HAV, HBV, HCV, HDV & HEV)
• 3.4 Disease Burden & Unmet Diagnostic Needs
• 3.5 Epidemiology and Prevalence Analysis
  • 3.5.1 Global Disease Prevalence
  • 3.5.2 Diagnosed Patient Population
• 3.6 Diagnostic Pathway & Testing Algorithm
• 3.7 Industry Evolution
• 3.8 Key Market Trends
• 3.9 Historical Market Size Analysis (2021-2025)
• 3.10 Market Forecast (2026-2035)

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Diagnostic Technologies
• 6.2 Product Innovation
• 6.3 Clinical Trial Analysis
• 6.4 Pipeline Analysis
• 6.5 Technology Roadmap
• 6.6 AI Integration in Hepatitis Diagnostics
• 6.7 Digital Health Integration

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Hepatitis Diagnostics Market Landscape Analysis

• 8.1 Analysis by Technology Platform
• 8.2 Analysis by Hepatitis Type
• 8.3 Analysis by Biomarker
• 8.4 Analysis by Sample Type
• 8.5 Analysis by Testing Methodology
• 8.6 Analysis by Clinical Application

9. Hepatitis Diagnostics Market Segment Analysis (2021-2035)

• 9.1 By Hepatitis Type
  • 9.1.1 Hepatitis A (HAV)
  • 9.1.2 Hepatitis B (HBV)
  • 9.1.3 Hepatitis C (HCV)
  • 9.1.4 Hepatitis D (HDV)
  • 9.1.5 Hepatitis E (HEV)
• 9.2 By Test Type
  • 9.2.1 Serology Tests
  • 9.2.2 Molecular Diagnostics
  • 9.2.3 Liver Function Tests
  • 9.2.4 Imaging & Biopsy
• 9.3 By Technology
  • 9.3.1 Enzyme-Linked Immunosorbent Assay (ELISA)
  • 9.3.2 Polymerase Chain Reaction (PCR)
  • 9.3.3 Next-Generation Sequencing (NGS)
  • 9.3.4 Others
• 9.4 By Sample Type
  • 9.4.1 Whole Blood
  • 9.4.2 Serum & Plasma
  • 9.4.3 Dried Blood Spot (DBS)
  • 9.4.4 Others
• 9.5 By End User
  • 9.5.1 Hospitals
  • 9.5.2 Diagnostic Laboratories
  • 9.5.3 Academic & Research Institutes
  • 9.5.4 Others

10. Hepatitis Diagnostics Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Hepatitis Diagnostics Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 China
• 11.9 Japan
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Mexico
• 11.15 Saudi Arabia
• 11.16 South Africa

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 F. Hoffmann-La Roche Ltd
  • 13.1.1 Company Overview
  • 13.1.2 Financials
  • 13.1.3 Product Portfolio
  • 13.1.4 Recent Developments
• 13.2 Abbott Laboratories
• 13.3 Siemens Healthineers
• 13.4 Danaher Corporation
• 13.5 bioMerieux
• 13.6 Bio-Rad Laboratories
• 13.7 QuidelOrtho Corporation
• 13.8 Hologic, Inc.
• 13.9 QIAGEN
• 13.10 Grifols S.A.

14. Hepatitis Diagnostics Market Commercial Forecast Analysis

• 14.1 Serology Testing
• 14.2 Molecular Diagnostic Testing
• 14.3 Rapid Diagnostic Testing
• 14.4 Liver Function Testing
• 14.5 Genotyping & Viral Load Testing

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends